Form 4: Biogen Executive Michael McDonnell Reports Stock Transactions
SEC Form 4 Filing
EVP and CFO Michael McDonnell reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.
Summary
- Michael McDonnell, EVP and Chief Financial Officer of Biogen Inc., reported transactions involving Biogen's common stock on February 10, 2025.
- These transactions involved the vesting of 3,257 restricted stock units and the subsequent disposition of 1,371 shares to satisfy tax withholding obligations.
- Following these transactions, McDonnell directly owns 24,341 shares of Biogen common stock.
Sentiment
Score: 5
Explanation: The document reflects routine executive compensation transactions, with no indication of unusual or concerning activity. Therefore, the sentiment is neutral.
Industry Context
Form 4 filings are a routine part of executive compensation and provide transparency into the trading activities of company insiders. The vesting of RSUs is a common form of equity compensation.
Comparison to Industry Standards
- Equity compensation, including restricted stock units, is a standard practice among publicly traded companies like Biogen to align executive interests with shareholder value.
- Companies such as Amgen (AMGN) and Gilead Sciences (GILD) also utilize RSUs as part of their executive compensation packages.
- The vesting schedules and tax withholding practices observed in this filing are consistent with industry norms.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they are part of standard executive compensation practices.
- Shareholders may view the transactions as a routine part of executive compensation.
Key Dates
| Date | Description |
|---|---|
| February 10, 2022 | Grant date of the restricted stock units, which vest in three equal yearly installments beginning on the first anniversary of this date. |
| February 10, 2025 | Date of the reported transactions: vesting of restricted stock units and disposition of shares for tax obligations. |
| February 12, 2025 | Date of signature for the Form 4 filing. |
Keywords
Biogen, BIIB, Michael McDonnell, Stock, Form 4, Restricted Stock Units, RSU, EVP, CFO, Beneficial Ownership, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.